Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithira Vasu

Showing results (21-30 of 102) with videos related to

Pageof 11
Sort By:
ESMO Open|September 9, 2020
Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour typesAmit A Kulkarni, Maryam Ebadi, Shijia Zhang, et al.
Leukemia & Lymphoma|January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemiaAlison R Walker, Hongyan Wang, Katherine Walsh, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 2, 2020
Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell LymphomaAllison Grana, Natalia Gut, Kiersten Williams, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 26, 2020
Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AMLNathaniel J Buteyn, Ramasamy Santhanam, Giovanna Merchand-Reyes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2014
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuriaJeremy Pantin, Xin Tian, Nancy Geller, et al.
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Oncotarget|March 9, 2018
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemiaBhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2019
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)Ravi Vij, Jennifer Le-Rademacher, Kristina Laumann, et al.
Transplantation and Cellular Therapy|March 6, 2022
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell LymphomaAudrey M Sigmund, Nathan Denlinger, Ying Huang, et al.
Transplantation and Cellular Therapy|June 24, 2026
Outcomes of Tocilizumab for Cytokine Release Syndrome After Post-Transplant CyclophosphamideTuan L Phan, Roberta Azbell, Hannah Choe, et al.
Pageof 11

Showing results (21-30 of 102) with videos related to

Sort By:
Pageof 11
ESMO Open|September 9, 2020
Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour typesAmit A Kulkarni, Maryam Ebadi, Shijia Zhang, et al.
Leukemia & Lymphoma|January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemiaAlison R Walker, Hongyan Wang, Katherine Walsh, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 2, 2020
Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell LymphomaAllison Grana, Natalia Gut, Kiersten Williams, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 26, 2020
Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AMLNathaniel J Buteyn, Ramasamy Santhanam, Giovanna Merchand-Reyes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2014
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuriaJeremy Pantin, Xin Tian, Nancy Geller, et al.
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Oncotarget|March 9, 2018
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemiaBhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2019
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)Ravi Vij, Jennifer Le-Rademacher, Kristina Laumann, et al.
Transplantation and Cellular Therapy|March 6, 2022
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell LymphomaAudrey M Sigmund, Nathan Denlinger, Ying Huang, et al.
Transplantation and Cellular Therapy|June 24, 2026
Outcomes of Tocilizumab for Cytokine Release Syndrome After Post-Transplant CyclophosphamideTuan L Phan, Roberta Azbell, Hannah Choe, et al.
Pageof 11